Cargando…

Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy

Obesity and type 2 diabetes mellitus (T2D) represent important comorbidities of the metabolic syndrome, which are associated with non-alcoholic fatty liver disease (NAFLD)-related hepatic fibrosis. In total, 160 morbidly obese patients—81 following a low-calorie formula diet (LCD) program and 79 und...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, Andreas, Arians, Miriam, Karrasch, Thomas, Pons-Kühnemann, Jörn, Schäffler, Andreas, Roderfeld, Martin, Roeb, Elke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999703/
https://www.ncbi.nlm.nih.gov/pubmed/35407364
http://dx.doi.org/10.3390/jcm11071756
_version_ 1784685252469325824
author Schmid, Andreas
Arians, Miriam
Karrasch, Thomas
Pons-Kühnemann, Jörn
Schäffler, Andreas
Roderfeld, Martin
Roeb, Elke
author_facet Schmid, Andreas
Arians, Miriam
Karrasch, Thomas
Pons-Kühnemann, Jörn
Schäffler, Andreas
Roderfeld, Martin
Roeb, Elke
author_sort Schmid, Andreas
collection PubMed
description Obesity and type 2 diabetes mellitus (T2D) represent important comorbidities of the metabolic syndrome, which are associated with non-alcoholic fatty liver disease (NAFLD)-related hepatic fibrosis. In total, 160 morbidly obese patients—81 following a low-calorie formula diet (LCD) program and 79 undergoing bariatric surgery (Roux-en-Y gastric bypass, RYGB)—were examined for anthropometric and metabolic parameters at base-line and during 12 months of weight loss, focusing on a putative co-regulation of T2D parameters and liver fibrosis risk. High NAFLD fibrosis scores (NFS) before intervention were associated with elevated HbA1c levels and T2D. Loss of weight and body fat percentage (BFL) were associated with improved glucose and lipid metabolism and reduced risk of NAFLD-related fibrosis, with particularly beneficial effects by RYGB. Both T2D improvement and NFS decrease were positively associated with high BFL. A highly significant correlation of NFS reduction with BFL was restricted to male patients while being absent in females, accompanied by generally higher BFL in men. Overall, the data display the relation of BFL, T2D improvement, and reduced NAFLD-related fibrosis risk during weight loss in morbidly obese individuals induced by diet or RYGB. Furthermore, our data suggest a considerable sexual dimorphism concerning the correlation of fat loss and improved risk of liver fibrosis.
format Online
Article
Text
id pubmed-8999703
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89997032022-04-12 Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy Schmid, Andreas Arians, Miriam Karrasch, Thomas Pons-Kühnemann, Jörn Schäffler, Andreas Roderfeld, Martin Roeb, Elke J Clin Med Article Obesity and type 2 diabetes mellitus (T2D) represent important comorbidities of the metabolic syndrome, which are associated with non-alcoholic fatty liver disease (NAFLD)-related hepatic fibrosis. In total, 160 morbidly obese patients—81 following a low-calorie formula diet (LCD) program and 79 undergoing bariatric surgery (Roux-en-Y gastric bypass, RYGB)—were examined for anthropometric and metabolic parameters at base-line and during 12 months of weight loss, focusing on a putative co-regulation of T2D parameters and liver fibrosis risk. High NAFLD fibrosis scores (NFS) before intervention were associated with elevated HbA1c levels and T2D. Loss of weight and body fat percentage (BFL) were associated with improved glucose and lipid metabolism and reduced risk of NAFLD-related fibrosis, with particularly beneficial effects by RYGB. Both T2D improvement and NFS decrease were positively associated with high BFL. A highly significant correlation of NFS reduction with BFL was restricted to male patients while being absent in females, accompanied by generally higher BFL in men. Overall, the data display the relation of BFL, T2D improvement, and reduced NAFLD-related fibrosis risk during weight loss in morbidly obese individuals induced by diet or RYGB. Furthermore, our data suggest a considerable sexual dimorphism concerning the correlation of fat loss and improved risk of liver fibrosis. MDPI 2022-03-22 /pmc/articles/PMC8999703/ /pubmed/35407364 http://dx.doi.org/10.3390/jcm11071756 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schmid, Andreas
Arians, Miriam
Karrasch, Thomas
Pons-Kühnemann, Jörn
Schäffler, Andreas
Roderfeld, Martin
Roeb, Elke
Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy
title Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy
title_full Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy
title_fullStr Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy
title_full_unstemmed Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy
title_short Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy
title_sort improvement of type 2 diabetes mellitus and attenuation of nafld are associated with the success of obesity therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999703/
https://www.ncbi.nlm.nih.gov/pubmed/35407364
http://dx.doi.org/10.3390/jcm11071756
work_keys_str_mv AT schmidandreas improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy
AT ariansmiriam improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy
AT karraschthomas improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy
AT ponskuhnemannjorn improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy
AT schafflerandreas improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy
AT roderfeldmartin improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy
AT roebelke improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy